Raymond James Financial and Cantor Fitzgerald raised target prices for InflaRx N.V., a stock traded on Nasdaq.
2 reports, 2 independent
Updated Sep 17
Gone quiet
- Reports
- 2
- Developments
- 2
- Repetition
- 0%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Raymond James Financial and Cantor Fitzgerald raised target prices for InflaRx N.V., a stock traded on Nasdaq.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Needham & Company initiated coverage on InflaRx shares alongside Cantor Fitzgerald's target price lift.1 source
Raymond James and Cantor Fitzgerald lifted price targets for InflaRx N.V.1 source
Keep exploring
The entities involved
-
Raymond James Financial
American Investment Bank and Financial Services Firm
-
Cantor Fitzgerald
American financial services company
Related events
- Cantor Fitzgerald raised its price target and rating for Supernus Pharmaceuticals, Inc. on September 2, 2026, and the company filed a disclosure with the SEC.
- Cantor Fitzgerald raised its price target on Texas Instruments shares on July 8, 2026.
- Cantor Fitzgerald raised its price target on Salesforce on September 1, 2026.
- Morgan Stanley and Cantor Fitzgerald raised target prices, while filings detailing stock changes were submitted to the SEC.
- Cantor Fitzgerald and Wells Fargo raised price targets for Regeneron Pharmaceuticals stock.